Christine Siu
Vermögen: - $ am 31.05.2026
Vermögen: - $ am 31.05.2026
Frau Christine E. Siu ist ein Chief Operating Officer bei BridgeBio Pharma, Inc. Sie ist Mitglied des Board of Directors bei Vividion Therapeutics, Inc. und Monte Rosa Therapeutics, Inc. Frau Siu war zuvor als Chief Financial & Accounting Officer bei Eidos Therapeutics, Inc. beschäftigt, als Chief Business Officer bei The Bluefield Project to Cure Frontotemporal Dementia, als Senior Director-Operations & Business Development bei Global Blood Therapeutics, Inc. als Principal bei Third Rock Ventures LLC, als Vice President bei Thomas, McNerney & Partners LLC, als Analystin bei Bear, Stearns & Co, Inc. und als Portfolio Manager bei Warburg Pincus LLC. Außerdem war sie Vorstandsmitglied bei NeuroTherapeutics Pharma, Inc. Sie erwarb ihren Bachelor-Abschluss an der University of Michigan und einen MBA an der Harvard Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.12.2020 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Direktor/Vorstandsmitglied | 04.05.2021 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Direktor/Vorstandsmitglied | 10.06.2021 |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| BRIDGEBIO PHARMA, INC. | Geschäftsführer | 23.07.2024 |
| EIDOS THERAPEUTICS, INC. | Finanzdirektor/CFO | 31.12.2019 |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | Corporate Officer/Principal | 01.01.2017 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Geschäftsführer | 01.01.2014 |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Private-Equity-Analyst | 31.12.2010 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 15 |
|---|---|
Bear, Stearns & Co., Inc.
Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Provides investment banking, securities trading and brokerage Services | Finance |
Warburg Pincus LLC
Warburg Pincus LLC Investment ManagersFinance Warburg Pincus invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for buyout transactions. | Finance |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Finance |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
NeuroTherapeutics Pharma, Inc.
NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical and therapeutic drugs for central nervous system disorders | Health Technology |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen